drugset / Trial / NCT07596693
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
Phase 1
Recruiting
30 enrolled
TCRx Therapeutics Co.Ltd
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
Timeline
- Start
- 2025-12-19
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KXV01 TCR Lentinvivo Injection | Unknown | — | — |